Rezdiffra Pregnancy and Lactation Registry

Recruiting now

Conditions studied: MASH - Metabolic Dysfunction-Associated Steatohepatitis

In brief

To evaluate pregnancy and clinical outcomes in women with NASH and their infants after exposure to Rezdiffra at any time during pregnancy and/or lactation.

Key facts

Study ID

NCT07541469

Run by

Madrigal Pharmaceuticals, Inc.

People needed

10

Starts

2026-03-04

Expected to finish

2030-04-08

Last updated by the study team

2026-04-21

Who can join

Age: any. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Female patients with NASH who have been exposed to at least 1 dose of resmetirom at any time during pregnancy (defined as having received resmetirom within 3 days prior to the date of conception and/or during pregnancy) and/or during lactation, and their infants (up to 12 months of age).
• Patient or parent/legally authorized representative must be able to understand and provide consent through an Institutional Review Board/Independent Ethics Committee (IRB/IEC)-approved informed consent or assent form.

You may not qualify if…

• NONE

Where it is running

• Madrigal Pharmaceuticals — West Conshohocken, Pennsylvania, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.